Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Neuroendocrine tumors (NETs) are highly vascularized, relying on angiogenesis for growth.
• Cabozantinib (CAB) is an emerging compound with potential antivascular properties.
• Understanding CAB's effect on NETs is crucial for developing new therapies.

Purpose of the Study:

• To analyze the antitumor activity of cabozantinib (CAB) against neuroendocrine tumors (NETs).
• To investigate CAB's effects on NET cell viability, proliferation, and cell cycle.
• To evaluate CAB's efficacy in preclinical NET models.

Main Methods:

• In vitro studies using BON-1, NCI-H727, and NCI-H720 NET cell lines.
• Cell viability assessed by manual count and fluorescence-activated cell sorting (propidium iodide exclusion assay).
• In vivo studies using mouse and zebrafish xenograft tumor models, including angiogenesis and migration assays.

Main Results:

• CAB demonstrated dose- and time-dependent inhibition of NET cell viability and proliferation.
• CAB induced cell cycle arrest at endoduplication, a novel finding for tyrosine kinase inhibitors.
• CAB significantly inhibited NET-induced angiogenesis and cell migration in a zebrafish model.

Conclusions:

• Cabozantinib exhibits significant antitumor activity against neuroendocrine tumors in vitro and in vivo.
• CAB's unique mechanism of cell cycle arrest warrants further investigation.
• These findings support further research into CAB as a potential therapeutic agent for NETs.